Clinical Research in Cardiology

, Volume 100, Issue 6, pp 483–491 | Cite as

Blood pressure management in a cohort of hypertensive patients in Germany treated by cardiologists

  • Martin Thoenes
  • Ulrich TebbeEmail author
  • Ludger Rosin
  • W. Dieter Paar
  • Peter Bramlage
  • Wilhelm Kirch
  • Michael Böhm
Original Paper



In Germany, an estimated 20–25 million patients suffer from hypertension. Blood pressure control rates are, however, lower than in many other European countries and the USA. The present analysis reports blood pressure treatment and control rates in Germany in patients with hypertension treated by cardiologists.


The present analysis reports data from a German subgroup analysis of a large, multinational, observational survey i-SEARCH that recruited patients in 2005/2006. It reports blood pressure readings, drug utilization and control rates in cardiology practice.


A total of 4,982 patients were documented at 417 sites. Mean systolic/diastolic blood pressure (SBP/DBP) was 152 ± 19.5/88.4 ± 11.5 mmHg. SBP was 1.3 mmHg higher in men than in women (p = 0.021). The majority of patients had an SBP between 141 and 160 mmHg and 31.4% of patients had normal SBP. Overall blood pressure control rate was only 11.6% [95% CI 10.7–12.6] in treated patients. It was different in men [10.2%; 95% CI 9.0–11.6] than in women [8.1%; 95% CI 7.1–9.4; p = 0.008] and higher in patients without diabetes [12.7%; 95% CI 11.6–14.0] than in those with diabetes [4.3%; 95% CI 3.4–5.4; p < 0.0001]. One-third of patients received either monotherapy or dual therapy, or three and more drugs, respectively; 42.2% of patients received guideline-recommended dual combination therapy. A combination of beta-blockers + ACE inhibitors was most frequently prescribed (30.8%).


Our data indicate a low level of blood pressure control, especially in patients at an increased risk for cardiovascular events, such as those with diabetes or cardiovascular comorbidities. Major efforts are required to improve hypertension management as recommend by current treatment guidelines.


Hypertension Blood pressure control Germany 



The authors would like to thank Sam Zhong for the statistical support provided. The study was supported by Sanofi-Aventis, Paris, France.

Conflict of interest

MT, LR and WDP are employees of the sponsors of the study. PB, MB, WK and UT have been consulting for Sanofi-Aventis and received speaker honoraria and research support.


  1. 1.
    Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J (2005) Global burden of hypertension: analysis of worldwide data. Lancet 365:217–223PubMedGoogle Scholar
  2. 2.
    Lawes CM, Vander Hoorn S, Rodgers A (2008) Global burden of blood-pressure-related disease, 2001. Lancet 371:1513–1518PubMedCrossRefGoogle Scholar
  3. 3.
    Wolf-Maier K, Cooper RS, Banegas JR, Giampaoli S, Hense HW, Joffres M, Kastarinen M, Poulter N et al (2003) Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 289:2363–2369PubMedCrossRefGoogle Scholar
  4. 4.
    Wolf-Maier K, Cooper RS, Kramer H, Banegas JR, Giampaoli S, Joffres MR, Poulter N, Primatesta P et al (2004) Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 43:10–17PubMedCrossRefGoogle Scholar
  5. 5.
    Sharma AM, Wittchen HU, Kirch W, Pittrow D, Ritz E, Goke B, Lehnert H, Tschope D et al (2004) High prevalence and poor control of hypertension in primary care: cross-sectional study. J Hypertens 22:479–486PubMedCrossRefGoogle Scholar
  6. 6.
    Bramlage P, Pittrow D, Wittchen H, Kirch W, Böhler S, Lehnert H, Höfler M, Unger T et al (2004) High body mass index is associated with an increased prevalence and lack of control of hypertension. Am J Hypertens 17:904–910PubMedCrossRefGoogle Scholar
  7. 7.
    Wong ND, Lopez VA, L’Italien G, Chen R, Kline SE, Franklin SS (2007) Inadequate control of hypertension in US adults with cardiovascular disease comorbidities in 2003–2004. Arch Intern Med 167:2431–2436PubMedCrossRefGoogle Scholar
  8. 8.
    Silber S, Richartz BM, Goss F, Haerer W, Glowatzki M, Schmieder RE (2007) Care of hypertensive patients seen by cardiologists: results of the Snapshot Hypertension Registry. Dtsch Med Wochenschr 132:2430–2435PubMedCrossRefGoogle Scholar
  9. 9.
    Bolen SD, Samuels TA, Yeh HC, Marinopoulos SS, McGuire M, Abuid M, Brancati FL (2008) Failure to intensify antihypertensive treatment by primary care providers: a cohort study in adults with diabetes mellitus and hypertension. J Gen Intern Med 23:543–550PubMedCrossRefGoogle Scholar
  10. 10.
    Geller JC, Cassens S, Brosz M, Keil U, Bernarding J, Kropf S, Bierwirth RA, Lippmann-Grob B et al (2007) Achievement of guideline-defined treatment goals in primary care: the German Coronary Risk Management (CoRiMa) study. Eur Heart J 28:3051–3058PubMedCrossRefGoogle Scholar
  11. 11.
    Bohm M, Thoenes M, Danchin N, Bramlage P, La Puerta P, Volpe M (2007) Association of cardiovascular risk factors with microalbuminuria in hypertensive individuals: the i-SEARCH global study. J Hypertens 25:2317–2324PubMedCrossRefGoogle Scholar
  12. 12.
    Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM et al (2007) 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 25:1105–1187PubMedCrossRefGoogle Scholar
  13. 13.
    Wittchen HU, Glaesmer H, Marz W, Stalla G, Lehnert H, Zeiher AM, Silber S, Koch U et al (2005) Cardiovascular risk factors in primary care: methods and baseline prevalence rates–the DETECT program. Curr Med Res Opin 21:619–630PubMedCrossRefGoogle Scholar
  14. 14.
    Voller H, Sonntag FJ, Thiery J, Wegscheider K, Luft FC, Bestehorn K (2006) Management of high-risk patients with hypertension and left ventricular hypertrophy in Germany: differences between cardiac specialists in the inpatient and outpatient setting. BMC Public Health 6:256PubMedCrossRefGoogle Scholar
  15. 15.
    Lloyd-Jones DM, Evans JC, Levy D (2005) Hypertension in adults across the age spectrum: current outcomes and control in the community. JAMA 294:466–472PubMedCrossRefGoogle Scholar
  16. 16.
    Abuful A, Gidron Y, Henkin Y (2005) Physicians’ attitudes toward preventive therapy for coronary artery disease: is there a gender bias? Clin Cardiol 28:389–393PubMedCrossRefGoogle Scholar
  17. 17.
    Holroyd-Leduc JM, Kapral MK, Austin PC, Tu JV (2000) Sex differences and similarities in the management and outcome of stroke patients. Stroke 31:1833–1837PubMedGoogle Scholar
  18. 18.
    Wexler DJ, Grant RW, Meigs JB, Nathan DM, Cagliero E (2005) Sex disparities in treatment of cardiac risk factors in patients with type 2 diabetes. Diabetes Care 28:514–520PubMedCrossRefGoogle Scholar
  19. 19.
    Meisinger C, Heier M, Volzke H, Lowel H, Mitusch R, Hense HW, Ludemann J (2006) Regional disparities of hypertension prevalence and management within Germany. J Hypertens 24:293–299PubMedCrossRefGoogle Scholar
  20. 20.
    Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, Cifkova R, Clement D et al (2009) Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Press 18:308–347PubMedCrossRefGoogle Scholar
  21. 21.
    Kreutz R (2006) Therapy of hypertension. Clin Res Cardiol 95(6):VI34–VI40PubMedCrossRefGoogle Scholar
  22. 22.
    Lindholm LH, Carlberg B, Samuelsson O (2005) Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 366:1545–1553PubMedCrossRefGoogle Scholar
  23. 23.
    Rahn KH (2009) Differential hypertensive therapy according to the guidelines. Internist (Berl) 50:433–441CrossRefGoogle Scholar
  24. 24.
    Krauss T, Schunkert H (2009) Management of hypertension (ESC Guideline 2007/DHL Guideline 2008). Herz 34:15–20PubMedCrossRefGoogle Scholar
  25. 25.
    Bramlage P, Hasford J (2009) Blood pressure reduction, persistence and costs in the evaluation of antihypertensive drug treatment—a review. Cardiovasc Diabetol 8:18PubMedCrossRefGoogle Scholar
  26. 26.
    Bramlage P, Wolf P-W, Stuhr T, Fronk E-M, Erdlenbruch W, Ketelhut R, Schmieder RE (2010) Effectiveness and tolerability of a fixed dose combination of olmesartan and amlodipine in clinical practice. Vasc Health Risk Manag 6:803–811PubMedCrossRefGoogle Scholar
  27. 27.
    Thevathasan L, Bramlage P (2010) Going beyond optimization of pharmacotherapy. Hypertens Res (in print)Google Scholar
  28. 28.
    Conen D, Tschudi P, Martina B (2009) Twenty-four hour ambulatory blood pressure for the management of antihypertensive treatment: a randomized controlled trial. J Hum Hypertens 23:122–129PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Martin Thoenes
    • 1
    • 2
  • Ulrich Tebbe
    • 3
    Email author
  • Ludger Rosin
    • 4
  • W. Dieter Paar
    • 4
  • Peter Bramlage
    • 5
  • Wilhelm Kirch
    • 1
  • Michael Böhm
    • 6
  1. 1.Institute for Clinical Pharmacology, Medical Faculty Carl Gustav CarusTechnical UniversityDresdenGermany
  2. 2.Sanofi-Aventis Global Medical AffairsParisFrance
  3. 3.Klinikum Lippe GmbHFachbereich Herz-Kreislauf-Lunge-NiereDetmoldGermany
  4. 4.Sanofi-Aventis, Abteilung MedizinBerlinGermany
  5. 5.Institute for Cardiovascular Pharmacology and EpidemiologyMahlowGermany
  6. 6.Klinik III für Innere Medizin, Kardiologie, Angiologie und IntensivmedizinUniversität des SaarlandesHomburg/SaarGermany

Personalised recommendations